
The study investigated the short-term preoperative octreotide treatment's impact on surgical outcomes of thyrotropin-secreting pituitary adenomas (TSHoma). Octreotide did not significantly improve tumor consistency, blood supply, gross total resection rates, or biochemical remission. Electron microscopy showed cellular impairments in octreotide-treated specimens. Octreotide's efficacy in enhancing surgical outcomes is limited, suggesting longer treatment may be needed for optimal tumor-shrinking effects.
Like
Save
Share